Literature DB >> 23806263

Clinical significance of carcinoembryonic antigen in peritoneal lavage from patients with gastric cancer.

Kengo Kanetaka1, Shinichiro Ito, Seiya Susumu, Akira Yoneda, Fumihiko Fujita, Mitsuhisa Takatsuki, Tamotsu Kuroki, Susumu Eguchi.   

Abstract

BACKGROUND: Peritoneal carcinomatosis is the most common pattern of recurrence of gastric cancer, and it is important to identify patients at high risk for recurrence. Although the carcinoembryonic antigen level in peritoneal lavage (pCEA) was reported to be a useful biomarker to predict peritoneal recurrence in a small series, its clinical significance has not been fully validated. We evaluated the clinical significance of pCEA in a large cohort of patients with gastric cancer.
METHODS: We prospectively analyzed the pCEA level in 597 patients with histologically proven gastric cancer who underwent laparotomy.
RESULTS: A significant relationship was demonstrated between the value of pCEA and clinicopathologic features, such as the peritoneal lavage cytology, peritoneal metastasis, the depth of tumor invasion, and the lymph node metastasis. The cutoff value was set at 100 ng/g of protein, and 134 of the 462 patients who underwent curative surgery had positive pCEA findings. The overall and the intraperitoneal-recurrence-related survival of patients positive for pCEA were significantly poorer than those of pCEA-negative patients. When we analyzed the patients with pathologic stage I through III gastric cancers separately, the pCEA-positive patients had poorer prognoses than the pCEA-negative patients who had stage III gastric cancer. In a univariate analysis, the tumor size, depth of tumor invasion, lymph node metastasis, histologic type, serum CEA (sCEA), and pCEA were found to affect the patients' outcomes, although a multivariate analysis found only the extent of lymph node metastasis to be an independent prognostic factor.
CONCLUSION: The pCEA level is a useful biomarker to predict gastric cancer-related death. Moreover, the pCEA level may be useful to identify a cohort of patients with gastric cancer who need more intensive adjuvant chemotherapy to improve their prognoses.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23806263     DOI: 10.1016/j.surg.2013.03.005

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

Review 1.  Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients.

Authors:  Shunsuke Kagawa; Kunitoshi Shigeyasu; Michihiro Ishida; Megumi Watanabe; Hiroshi Tazawa; Takeshi Nagasaka; Yasuhiro Shirakawa; Toshiyoshi Fujiwara
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

2.  Use of serum and peritoneal CEA and CA19-9 in prediction of peritoneal dissemination and survival of gastric adenocarcinoma patients: are they prognostic factors?

Authors:  M Hasbahceci; F U Malya; E Kunduz; M Guzel; N Unver; A Akcakaya
Journal:  Ann R Coll Surg Engl       Date:  2018-03-15       Impact factor: 1.891

3.  The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients.

Authors:  Kai Deng; Li Yang; Bing Hu; Hao Wu; Hong Zhu; Chengwei Tang
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

Review 4.  Detection value of free cancer cells in peritoneal washing in gastric cancer: a systematic review and meta-analysis.

Authors:  Francisco Tustumi; Wanderley Marques Bernardo; Andre Roncon Dias; Marcus Fernando Kodama Pertille Ramos; Ivan Cecconello; Bruno Zilberstein; Ulysses Ribeiro-Júnior
Journal:  Clinics (Sao Paulo)       Date:  2016-12-01       Impact factor: 2.365

5.  Circulating methylated THBS1 DNAs as a novel marker for predicting peritoneal dissemination in gastric cancer.

Authors:  Xuan-Yu Hu; Zhe-Nan Ling; Lian-Lian Hong; Qi-Ming Yu; Pei Li; Zhi-Qiang Ling
Journal:  J Clin Lab Anal       Date:  2021-08-13       Impact factor: 2.352

Review 6.  Classic tumor markers in gastric cancer. Current standards and limitations.

Authors:  Călin Căinap; Viorica Nagy; Alexandra Gherman; Sanziana Cetean; Istvan Laszlo; Anne-Marie Constantin; Simona Căinap
Journal:  Clujul Med       Date:  2015-04-15

7.  Adenoviral targeting using genetically incorporated camelid single variable domains.

Authors:  Sergey A Kaliberov; Lyudmila N Kaliberova; Maurizio Buggio; Jacqueline M Tremblay; Charles B Shoemaker; David T Curiel
Journal:  Lab Invest       Date:  2014-06-16       Impact factor: 5.662

8.  Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein.

Authors:  Elisabeth A van Erp; Lyudmila N Kaliberova; Sergey A Kaliberov; David T Curiel
Journal:  Mol Ther Oncolytics       Date:  2015-02-18       Impact factor: 7.200

9.  Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but not preoperative biomarkers: a single-institution study of 320 cases.

Authors:  Fan Wu; Chunmei Shi; Riping Wu; Zhiqing Huang; Qiang Chen
Journal:  Oncotarget       Date:  2017-05-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.